A Randomized Study of the Safety, Tolerability, and Pharmacokinetics of AZ-009 (Staccato Apomorphine) in Healthy Volunteers and the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZ-009 in Subjects With Parkinson's Disease
Latest Information Update: 31 Jan 2022
Price :
$35 *
At a glance
- Drugs Apomorphine (Primary) ; Apomorphine
- Indications Parkinson's disease
- Focus Pharmacokinetics
- Sponsors Alexza Pharmaceuticals
- 20 Jan 2022 Results assessing the compare the safety and pharmacokinetics of inhaled apomorphine (AZ-009) with subcutaneous apomorphine (APO-go PEN) in healthy volunteers (HVs) and to examine the safety, pharmacokinetics, and efficacy of AZ-009 in patients with PD, published in the Movement Disorders.
- 19 Aug 2019 Status changed from recruiting to completed.
- 01 Feb 2019 New trial record